Particology joins £8.2 mill medicines manufacture consortium
14 Dec 2025
Particle science contract research and development organisation Particology has been chosen to join the £8.2 million government-funded consortium charged with improving the manufacture of medicines in the UK.
It is one of eight ‘Grand Challenge’ research projects funded within Innovate UK’s £54 million Sustainable Medicines Manufacturing Innovation Programme and will run for three and a half years.
Particology, based at Discovery Park in Kent, provides lab and consultancy services for life science and pharmaceutical organisations specialising in small molecule innovation.
Within the consortium, it will be responsible for leading on the crystallization of active pharmaceutical ingredients, employing state of the art advanced photonic and spectroscopy techniques.
The objective will be to improve crystallisation quality in order to reduce materials and power use and also waste products.
Deputy director for medicines manufacturing at Innovate UK Mark Talford said: "This collaboration will not only advance cutting-edge crystallisation technologies but also create high-value jobs and expertise, reinforcing Kent’s long-standing role in the UK’s life sciences sector and helping keep the UK at the forefront of global pharmaceutical manufacturing."
Early investment from the consortium has enabled the company to hire a new spectroscopy research associate for the start of Particology’s work on the project in January.
Company chief operating officer Dr John Murphy remarked: "This innovative programme will transform the future of medicines manufacture, making production more efficient and sustainable.”
